Fx-5A
Phase 1- Indications
- Cardiovascular diseases
Company intelligence / Profile preview
KineMed developed proprietary translational medicine technologies enabling real-time measurement of biochemical pathway activity in both preclinical models and humans. The company partnered with major pharma companies to develop kinetic biomarkers but does not appear to have advanced its own drugs into late-stage clinical trials before becoming inactive.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KineMed, Inc..